Testing a simpler severity score for bullous pemphigoid
Part of Immune system & allergy, Skin clinical trials.
This trial checks whether a simplified skin-judge score (called the Investigator Global Assessment) matches real disease severity in people with bullous pemphigoid. If your care team can score severity more easily and reliably, it may help track your response to treatment over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult age 18 or older.
- You have bullous pemphigoid that is newly diagnosed or has come back (relapsed).
- Your diagnosis fits classic bullous pemphigoid based on skin exam, biopsy (tissue changes), and antibody findings (IgG and/or C3 on a specific skin layer).
- Blood testing shows the right type of anti-skin antibodies that label the skin side of a test called salt-split skin.
- Your case does not look like a different related condition, such as mucous membrane pemphigoid, pemphigoid gestationis, linear IgA dermatosis, or epidermolysis bullosa acquisita.
- You understand the study information and agree to participate, including attending follow-up visits and following study instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a specific immune system protein (IL-17) affects inflammation in a blistering skin disease called Bullous Pemphigoid. It aims to better understand the disease to help develop future treatments.
This study is for adults with certain autoimmune blistering skin conditions. Researchers want to better understand and test treatments that could improve symptoms and healing for people with these specific diseases.
This study collects skin samples and medical information from people with skin conditions caused by their immune system. It helps researchers better understand these diseases and develop new treatments.
This trial tests a new drug called CM313 for people with moderate to severe pemphigus, a blistering skin condition. It's for patients who haven't had this treatment before and may have not responded well to other therapies.
This trial tests a new injectable drug, Stapokibart, for people with moderate to severe bullous pemphigoid, a blistering skin condition. The goal is to see if the drug can help reduce blistering and itching.
This study looks at how immune-related skin diseases like bullous pemphigoid and lupus affect blood clotting. The results could help doctors better understand and manage clotting risks in these patients.
Hear when a new Bullous Pemphigoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.